Response to apheretic platelet transfusion in children of acute lymphoblastic leukemia receiving induction chemotherapy: a cross-sectional study from Bangladesh

Author:

Basak Sushanta Kumar1,Iktidar Mohammad Azmain2,Chowdhury Romana3,Khatun Ayesha4,Rahman Atiar4,Miah Sonia Shormin4,Shaheen Sheikh Saiful Islam4,Mazumder Sudeshna5

Affiliation:

1. Sheikh Hasina National Institute of Burn and Plastic Surgery

2. Directorate General of Health Services (DGHS)

3. Department of Transfusion Medicine, Sirajul Islam Medical College

4. Bangabandhu Sheikh Mujib Medical University, Dhaka

5. Chattogram Medical College Hospital, Chattogram, Bangladesh

Abstract

Background: Disease and therapy-related hypoproliferative thrombocytopenia is a significant barrier to managing acute lymphoblastic leukaemia (ALL) patients. To reduce the risk of haemorrhage, apheretic platelet transfusion is a modern, effective, and expensive option. Since most ALL patients in Bangladesh have financial constraints, this study can shed light on the magnitude of benefit regarding the effectiveness of apheretic platelet prophylactically and therapeutically in children of ALL receiving induction chemotherapy. Materials and methods: This observational cross-sectional study was conducted in the department of transfusion medicine and the department of paediatric haematology and oncology at a tertiary level hospital in Bangladesh from June 2020 to June 2021. A total of 33 cases of ALL were enroled in this study according to inclusion and exclusion criteria. After receiving written informed consent, relevant data were collected using a face-to-face interview with the guardian of the patients, thorough clinical examination, and relevant investigation. After the collection of all the required data, analysis was done by Stata (v.16). Results: Mean age of the patients was 7.39±4.46 (SD), ranging from 1 to 18 years. The majority of children were aged younger than or equal to 10 years (69.70%). Male children were slightly predominant (51.5%). Significant post-transfusion platelet increment (Median pre-transfusion count 16×103/μl vs. Median post-transfusion count 133×103/μl, P<0.001) was observed. WHO bleeding grades also improved after apheretic platelet transfusion (P<0.05). Age was a significant factor associated with corrected count increment (CCI) in both univariate and multivariate analysis. In subgroup analysis, age and gender were significant predictors of CCI in therapeutic transfusion group but not in prophylactic transfusion group. Conclusions: Significant improvement in bleeding status and platelet count was observed following apheretic platelet transfusion.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference25 articles.

1. Normal platelet function;Holinstat;Cancer Metastasis Rev,2017

2. Prevention and management of platelet transfusion refractoriness;Novotny;Vox Sang,1999

3. Whole blood transfusion versus component therapy in adult trauma patients with acute major haemorrhage;Avery;Emerg Med J,2020

4. Platelet transfusion goals in oncology patients;RossM;Am Soc Hematol,2015

5. Acute lymphoblastic leukemia: a comprehensive review and 2017 update;Terwilliger;Blood Cancer J,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3